Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,813 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07352527Recruiting
New blood test for adrenal nodule diagnosis
This trial is testing a new method (using a blood test that measures steroid hormones) to better diagnose whether adrenal nodules are causing mild hormone problems. It may help doctors decide if you need treatment or just monitoring.
PessacAges 18 years+ - NCT07352852Recruiting
Rapamycin-coated stent for narrowed brain arteries
This study tests a special stent that slowly releases a drug (rapamycin) to keep a narrowed brain artery open. It is for patients who have had strokes despite medical treatment.
Qingdao, ShandongAges 18–80 - NCT07353255Recruiting
Comparing two tools for nose breathing tube placement
This trial compares two methods (fibrescope vs videolaryngoscope) for placing a breathing tube through the nose during surgery. It aims to find which technique is easier and safer for patients like you.
Coventry, West MidlandsAges 18 years+ - NCT07353502Recruiting
Early Alzheimer's brain connection study
This study looks at a specific brain pathway that may be linked to early memory loss in Alzheimer's disease. It compares people with early Alzheimer's to healthy older adults to understand how connections between brain cells start to break down.
Yiwu, ZhejiangAges 50 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07354048Recruiting
Thyroid health and its effect on liver function
This study looks at how thyroid problems (both overactive and underactive) may affect liver function tests. It aims to help researchers understand the link between thyroid and liver health.
SohagAges 20–60 - NCT07354269RecruitingPhase 4
Polio vaccine study for adolescents and adults
This trial tests a polio vaccine (sIPV) in healthy people aged 7-50 years. It aims to see how safe and effective the vaccine is, and may help protect against polio.
Dingxi, GansuAges 3 months–50 years - NCT07355842Recruiting
Can slow brain waves slow Parkinson's?
This study tests whether playing soft sounds during deep sleep can slow down brain changes in people with REM sleep behavior disorder (a condition linked to Parkinson's disease). It is for people who have this sleep disorder or were recently diagnosed with Parkinson's, and are not yet on Parkinson's medications.
Zurich, Canton of ZurichAges Any age - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07356778RecruitingPhase 4
Study of sotatercept for Eisenmenger syndrome patients
This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.
Fukuoka, Not Required For This CountryAges 18 years+ - NCT07357428Recruiting
Brain-computer implant study for severe paralysis or speech loss
This study tests a brain-computer implant that might help people with severe paralysis or speech loss control a computer with their thoughts. It is for people who have trouble moving and speaking due to a progressive disease or injury.
Sacramento, CaliforniaAges 22–75 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT07358572Recruiting
Eye-brain-kidney study in chronic kidney disease
This study is looking at how chronic kidney disease (CKD) affects the eyes, brain, and kidneys. It uses MRI scans to examine these organs, and aims to find connections that could help improve care for people with CKD.
Beijing, Beijing MunicipalityAges 18–70 - NCT07358832Recruiting
Brain stimulation for vision loss after recent brain injury
This trial tests whether combining brain stimulation with visual exercises can help improve vision loss caused by a recent brain injury. It is designed for people in the early recovery phase (within 3 months of injury) who have visual field deficits, but not other conditions like neglect or eye movement problems.
Milan, LombardyAges 18 years+ - NCT07359430Recruiting
Deep phenotyping of chronic inducible urticaria
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
Leiden, South HollandAges 18 years+ - NCT07360886Recruiting
Early detection of brain conditions in active drivers
This study looks at how well doctors can spot early signs of certain brain conditions in people who drive. You may join if you have a valid license, are between 18 and 85, and have one of the neurological diagnoses the study is focusing on.
Olomouc, Olomouc RegionAges 18–85 - NCT07360899Recruiting
Closing the left atrial appendage during heart surgery to prevent stroke
This trial tests if closing the left atrial appendage with a special stitch during planned heart surgery can help prevent strokes in people with atrial fibrillation. If you already need heart surgery, this extra step may reduce your future stroke risk.
Kamenitz, VojvodinaAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT07362875Recruiting
Muscle imaging study for myotonic dystrophy
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
Winston-Salem, North CarolinaAges 18–65 - NCT07364474Recruiting
Immune response to liver perfusion therapy for eye melanoma
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Boston, MassachusettsAges 18 years+ - NCT07364617RecruitingPhase 2
Fecal transplant for steroid-resistant gut GVHD
This study tests if a fecal transplant (transferring healthy bacteria from a donor's stool into your gut) can help people with severe gut graft-versus-host disease that hasn't responded to steroids. It's for patients who have had a stem cell transplant and now have ongoing, severe gut symptoms.
TaoyuanAges Any age - NCT07364773Recruiting
Motivational interviewing to boost rehab in spinal cord injury
This study looks at whether motivational interviewing—a supportive conversation style—can help patients with spinal cord injury (SCI) participate more fully in their rehab therapy. If you are an adult with SCI receiving inpatient rehab at certain hospitals, you may be able to join.
Chicago, IllinoisAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,813 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.